Neurocrine Biosciences (NBIX) Misses Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Neurocrine Bio. (NBIX) PT Raised to $100 at Oppenheimer
February 14, 2018 6:21 AM ESTOppenheimer raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $100.00 (from $95.00) while maintaining a Outperform rating following Q4 results.
Analyst Jay Olson commented, "NBIX shares have outperformed YTD (+8% vs. NBI +1% and S&P 500 flat), largely driven by impressive 4Q17 sales of... More
